Physician Office Labs At Cholestech’s Fingertips: CRP, Waived Tests In Reach
This article was originally published in The Gray Sheet
Executive Summary
Cholestech will conduct clinical studies to support Medicare reimbursement for Endo-Pat 2000, a device that measures vascular endothelial dysfunction, an early-stage marker of atherosclerosis
You may also be interested in...
CRP Coronary Disease Test Value Challenged By Icelandic Study – NEJM
C-reactive protein diagnostics offered little diagnostic benefit for coronary disease detection in a large prospective Icelandic study published in the April 1 New England Journal of Medicine.
Itamar Pursuing Sleep Apnea As First Application Of PAT Platform
Respironics will distribute Itamar Medical's peripheral arterial tonometry technology (PAT) with its sleep monitoring instruments to assist in the diagnosis of sleep apnea.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.